American Shared Hospital Announces Q3 EPS of 0c Compared to (3c) Last Year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 13 2025
0mins
Q3 Revenue Growth: The company reported a Q3 revenue of $7.2 million, an increase from $6.999 million the previous year, driven by growth in direct patient care services and new physician ramp-up in Rhode Island.
Expansion in Mexico: The new radiation therapy center in Puebla, Mexico, has seen significant revenue growth, with expectations for further expansion from a new Gamma Knife center in Guadalajara, set to start in Q2 2026.
Gamma Knife Revenue Increase: There was a notable period-over-period increase in Gamma Knife revenue during the third quarter, indicating strong performance in this segment.
Long-term Partnership: The company announced a 10-year extension with an existing health system for the latest model Gamma Knife System, the Esprit, highlighting ongoing partnerships and future revenue potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMS
About AMS
American Shared Hospital Services is a provider of turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. Its segments include Leasing and Retail. The Leasing segment comprises the Company’s medical equipment leasing. The Retail segment comprises facilities in Peru and Ecuador. Its Proton Beam Radiation Therapy Operations is an alternative to traditional external beam, photon-based radiation delivered by linear accelerators. Its Gamma Knife stereotactic radiosurgery, a non-invasive procedure, is an alternative to conventional brain surgery and/or radiation therapy. The Gamma Knife treats selected malignant and benign brain tumors, arteriovenous malformations, and functional disorders including trigeminal neuralgia (facial pain). It can be an adjunct to conventional brain surgery, radiation therapy, or chemotherapy. The Company provides radiation therapy services both domestically and internationally.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UK Stock Market Declines, Hochschild Mining Undervalued by 48.9%
- Market Decline: The UK stock market, represented by the FTSE 100 and FTSE 250 indices, has recently faced declines due to weak trade data from China, highlighting the interconnectedness of global economies and prompting investors to navigate market uncertainties cautiously.
- Hochschild Mining Valuation: Trading at £5.73, Hochschild Mining is significantly undervalued compared to its estimated fair value of £11.22, indicating a 48.9% discount; despite recent declines in gold and silver production, the company forecasts a robust annual earnings growth of 40.8% over the next three years, surpassing UK market averages.
- Pan African Resources Outlook: Priced at £1.28, Pan African Resources is below its estimated fair value of £1.63, with expected annual earnings growth of 31.3% over the next three years, bolstered by its inclusion in multiple FTSE indices, enhancing production capabilities and operational efficiencies.
- Raspberry Pi Holdings Growth Potential: Raspberry Pi Holdings is trading at £2.9, below its estimated fair value of £3.28, with anticipated annual earnings growth of 46.2%; despite recent executive changes, the company is expected to achieve a 16.8% revenue increase, indicating strong financial performance potential.
Continue Reading
10 Undervalued Stocks Identified Amid UK Market Decline
- Market Challenges: The recent decline of the FTSE 100 and FTSE 250 indices, driven by weak trade data from China, highlights uncertainty in the UK market, prompting investors to seek undervalued stocks to navigate these pressures.
- Undervalued Stocks: Vistry Group is currently priced at £6.26 with an estimated fair value of £12.30, reflecting a 49% discount, indicating potential value that may attract value investors' interest.
- Growth Potential: Advanced Medical Solutions Group is forecasted to grow at 33.8% annually, significantly outpacing the UK market's 14.2% growth rate, suggesting substantial future financial growth despite a decline in profit margins.
- Financial Health: GB Group, with a market cap of £608.22 million, is projected to see earnings growth of 38.8% per year, showcasing strong performance in the identity data intelligence sector, despite modest revenue growth, making it an attractive investment opportunity.
Continue Reading